Press Releases

No. 31 | 14. May 2018 | by Eck

"Universal antibodies" disarm various pathogens

The common pathogen Klebsiella pneumoniae
© Niaid, Wikimedia

Scientists from the German Cancer Research Center (DKFZ) have been studying how the immune system succeeds in keeping pathogens in check. For the first time, the researchers have now discovered antibodies that are capable of disarming not only one specific bacterium but a whole variety of microorganisms at once. The newly discovered antibodies recognize a tiny sugar structure found on the surface of various germs. Thus, a limited number of antibodies is sufficient to control a wide variety of microorganisms.

read more

No. 30 | 11. May 2018 | by Mat

Genetic analysis for certain childhood brain tumors soon a standard-of-care?

MRT picture of a medulloblastoma
© Wikimedia/Hellerhoff

An international team of researchers from the Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), the European Molecular Biology Laboratory (EMBL) and the German Cancer Consortium (DKTK) together with colleagues at the St. Jude Children's Research Hospital in Memphis and the Hospital for Sick Children in Toronto has summarized hereditary gene defects which can trigger the development of certain malignant brain tumors (medulloblastoma). From their findings, the team has derived recommendations for routine genetic screening in medulloblastoma patients.
The "Hopp Children's Cancer Center at the NCT Heidelberg" (KiTZ) is a joint initiative of Heidelberg University Hospital and the German Cancer Research Center (DKFZ).

read more

No. 29a | 07. May 2018 | by Koh

High science distinction for Michael Baumann

Michael Baumann
© Philip Benjamin, NCT Dresden

At its 100th Annual Meeting, the American Radium Society honored Michael Baumann, Chairman and Scientific Director of the German Cancer Research Center (DKFZ), with the Janeway Gold Medal. The medal, which is awarded for outstanding contributions in cancer therapy, is one of the most prestigious distinctions in radiation oncology.

read more

No. 25c3 | 19. April 2018 | by Koh

ERC Advanced Grants for Hellmut Augustin and Christof Niehrs

Hellmut Augustin

The European Research Council ERC's Advanced Grants promote visionary projects of fundamental research. This year, Hellmut Augustin (University of Heidelberg and DKFZ) and Christof Niehrs (University of Mainz and DKFZ) received the prestigious funding.

read more

No. 25c2 | 18. April 2018 | by Eck

Cancer therapy: An interaction map of genes shows the best targets

© Benedikt Rauscher/DKFZ

Most genes are team players. Only when interacting with other genes can they perform properly. Scientists from the German Cancer Research Center (DKFZ) have now found a possibility to exploit this for the development of new cancer therapies. They generate maps of genetic interactions in cancer cells. These maps can then be used to determine the sites where it would be most effective to interfere with the interplay of cancer genes.

read more

No. 25c | 13. April 2018 | by Koh

Alcohol: redefined upper limit for low-risk consumption

© Gina Sanders, Fotolia

Consuming regularly more than 100 grams of alcohol per week shortens life, according to the results of an international research consortium published in the latest issue of the journal "Lancet". Those who consistently consume more than two liters of beer or a bottle of wine per week risk more strokes, deadly aneurysms and heart failure, and a higher overall mortality.

read more

No. 25 | 09. April 2018 | by Koh

Breast cancer therapy: All clear for the heart

© Chombosan, Fotolia

Many breast cancer therapies cause damage to the heart. However, in the largest study of its kind so far, scientists from the German Cancer Research Center (DKFZ) in Heidelberg have now shown that the risk of death from heart disease in breast cancer patients following radiotherapy or chemotherapy is no higher than it is among the average population. Good risk management in the hospitals as well as control screenings at short intervals seem to make up for elevated risks.

read more

No. 24 | 06. April 2018 | by Koh

Blood test indicates risk of developing Alzheimer’s disease

Pathological deposits of amyloid-beta in the brain of people with Alzheimer...
© K. Gerwert, A. Nabers / RUB

A newly developed blood test may indicate Alzheimer's disease on average eight years before the clinical diagnosis. This was demonstrated by scientists from the Ruhr University Bochum (RUB), the German Cancer Research Center (DKFZ) and the Saarland Cancer Registry with a large population-based cohort study from the Saarland.
Joint press release of Ruhr University Bochum and German Cancer Research Center

read more

No. 22 | 03. April 2018 | by Koh

Double success for Heidelberg stem cell researchers

Simon Raffel, Lars Velten and Simon Haas.
© Jutta Jung/DKFZ

Two awards at once, both carrying high monetary prizes, go to young researchers from the Heidelberg Institute for Stem Cell Research and Experimental Medicine (HI-STEM) at the German Cancer Research Center (DKFZ): Simon Raffel will receive the 2018 Walter Schulz Prize for his discovery how misregulated breakdown of amino acids in leukemia stem cells promotes blood cancer. Simon Haas will share the 2018 Otto Schmeil Prize with his colleague Lars Velten from EMBL. The two stem cell researchers have jointly demonstrated that the development of blood cells in the bone marrow follows very different paths from what scientists have assumed up to now.

read more

No. 21c | 22. March 2018

LifeTime - a visionary proposal for an EU Flagship

© Spencer Phillips, EMBL-EBI

Reliably predicting the onset and trajectory of a disease might seem like a distant dream. But a European consortium is aiming to achieve exactly this using a set of emerging technologies with the analysis of single cells at their core. Researchers from leading European science institutions have now submitted a proposal for a so-called "Future and Emerging Technologies Flagships". The large-scale project, which also involves scientists from the German Cancer Research Center, is called LifeTime.

read more


Subscribe to our RSS-Feed.

to top